期刊文献+

科华ELISA与雅培i2000sr检测系统对4种感染性疾病8项血清标志物检测的性能评价 被引量:3

Performance Evaluation of Kehua ELISA and Abbott i2000sr in Eight Serum Markers Detection for Four Infectious Diseases
下载PDF
导出
摘要 目的对科华ELISA和雅培i2000sr检测系统4种感染性疾病8项血清学标志物的性能进行评价和比较。方法采用美国临床和实验室标准协会(clinical and laboratory standards institute,CLSI)评价方案(evaluation protocols,EP)评价两种检测系统性能。评价内容包括:准确度、检出限、一致性、精密度、线性范围。结果两种检测系统的准确度均为100%。HBsAg,HBsAb,HBeAg,HBeAb,HBcAb,Anti-HCV,梅毒特异性抗体及(Anti-TP)Anti-HIV的检出限科华分别为0.08IU/ml,10mIU/ml,0.8NCU/ml,4.4NCU/ml,3.2NCU/ml,0.8NCU/ml,20mIU/ml和0.5NCU/ml;雅培分别为0.05IU/ml,10mIU/ml,0.23NCU/ml,1NCU/ml,1.8NCU/ml,0.45NCU/ml,20mIU/ml和2.88NCU/ml。一致性验证:两种系统方法学比对Kappa值分布于0.8~0.9,定性项目仪器间比对Kappa值均为1,定量项目(HBsAg,HBsAb)仪器间比对观察误差<1/2TEa,浓度误差指数绝对值<1。精密度评价:批内变异系数(CV)范围为1.10%~7.01%,室内CV范围为1.90%~10.03%。雅培i2000sr HBsAg,HBsAb线性范围分别为0.73~245IU/ml和4.21~960.89mIU/ml。结论科华ELISA和雅培i2000sr准确度、检出限、一致性、精密度和线性范围与厂家声明一致并能满足实验室要求。两种系统HBsAg,HBsAb,Anti-TP检出限接近,但HBeAg,HBeAb,HBcAb,Anti-HCV和Anti-HIV检出限二者存在较大差异。 Objective The present study was carried out to evaluate the performance of Kehua ELISA and Abbott i2000 sr for eight serum markers detection.Methods The performances,i.e.,accuracy,limit of detection(LOD),consistency,precision and linear range were evaluated according with the CLSI EP documents.Results The accuracy of the two systems were100%.The LOD of HBsAg,HBsAb,HBeAg,HBeAb,HBcAb,Anti-HCV,Anti-TP and Anti-HIV were 0.08 IU/ml,10 mIU/ml,0.8 NCU/ml,4.4 NCU/ml,3.2 NCU/ml,0.8 NCU/ml,20 mIU/ml and 0.5 NCU/ml for Kehua,and 0.05 IU/ml,10 mIU/ml,0.23 NCU/ml,1 NCU/ml,1.8 NCU/ml,0.45 NCU/ml,20 mIU/ml and 2.88 NCU/ml for Abbott,respectively.The consistency test showed that the Kappa value was 0.8 to 0.9 for method comparison and 1 for instruments comparison.Multiple instruments comparison for HBsAg and HBsAb,the observed error was<1/2 TEa and error index by concentration was<1.The coefficients of variations(CV)of within-run and laboratory precision were 1.10% ~7.01% and 1.90~10.03%,respectively.The linear ranges of HBsAg and HBsAb were 0.73~245 IU/ml and 4.21~960.89 mIU/ml,respectively.Conclusion The performances of two systems,such as LOD,consistency,precision and linear range,were consistent with manufacturer’s declaration and met the clinical requirements.Kehua was close to i2000 sr on the detection ability of HBsAg,HBsAb and Anti-TP,however,obvious difference in the detection ability of HBeAg,HBeAb,HBcAb,Anti-HCV and anti-HIV was observed between two systems.
作者 汪靖园 王林川 肖尧 阮竞雄 田旭东 闫芳 WANG Jing -yuan, WANG Lin- chuan,XIAO Yao, RUAN Jing -xiong, TIAN Xu- dong, YAN Fang(Department of Clinical Laboratory, the First Affiliated Hospital of Xi ' an Jiaotong University, Xi' an 710061, China; Department of Blood Transfusion, Xi' an No. 3 Hospital, Xi' an 710018, China)
出处 《现代检验医学杂志》 CAS 2018年第6期125-131,共7页 Journal of Modern Laboratory Medicine
基金 陕西省自然科学基金资助项目(No.2017JM8121)
关键词 科华ELISA 雅培i2000sr 血清标志物 性能评价 kehua ELISA Abbott i2000sr serum markers performance evaluatation
  • 相关文献

参考文献5

二级参考文献30

  • 1杨玉然,山海鹰,张丽.雅培Architect ci8200生化免疫联体机的性能与评价[J].医疗设备信息,2006,21(1):65-67. 被引量:5
  • 2夏邦世,吴金华.Kappa一致性检验在检验医学研究中的应用[J].中华检验医学杂志,2006,29(1):83-84. 被引量:217
  • 3Fried MW^Piravisuth T,Lau GK’et al. HBeAg and hepatitis B vi-rus DNA as outcome predictors during therapy with peginterferoncr2a for HBeAg-positive chronic hepatitis B [ J]. Hepatology,2008,47(2):428-434.
  • 4Wiegand J,Wedemeyer H, Finger A,et al. A decline in hepatitis Bvirus surface antigen ( HBsAg) predicts clearance, but does notcorrelate with quantitative HBeAg or HBV DNA levels[J], Anti-vir Ther,2008,13(4) :547-554.
  • 5NCCLS. User protocol for evaluation of qualitative test performafiee proposed guideline [ S]. Wayne, PA, USA.. NCCLS, 2002.
  • 6中国合格评定国家认可委员会.cNAsCL39:医学实验室质量和能力认可准则在临床免疫学检验领域的应用说明[s].北京:中国合格评定国家认可委员会.2012.
  • 7NGUYEN T,THOMPSON AJ,BOWDEN S,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia [J]. J Hepatol,2010,52(4):508-513.
  • 8CHAN HL,WONG VW,CHIM AM,et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B[J]. Aliment Pharmacol Ther, 2010,32(11-12):1323-1331.
  • 9CHAN HL,THOMPSON A,MARTINOT-PEIGNOUX M,et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report[J]. J Hepatol,2011,55(5):1121-1131.
  • 10BRUNETTO MR,MARCELLIN P,CHERUBINI B,et al. Response to peginterferon alfa-2a(40KD) in HBeAg-negative CHB:on-treatment kinetics of HBsAg serum levels vary by HBV genotype[J]. J Hepatol,2013,59(6):1153-1159.

共引文献28

同被引文献23

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部